Sireesh Appajosyula has served as a member of the board of directors of Tharimmune since July 2021 and joined as Chief Operating Officer in July 2023. Previously he was SVP, Corporate Development and Operations of 9 Meters (Nasdaq: NMTR), and since 2018 has served as Managing Member of Highpoint Pharmaceuticals, LLC, a pharmaceutical research and development company. Dr. Appajosyula spent over 8 years at Salix Pharmaceuticals (Nasdaq: SLXP) in various roles in medical affairs, product commercialization and business development until its acquisition by Bausch Health (Nasdaq: BHC). Prior to Salix, he was involved in various roles at Amgen, Critical Therapeutics (acq. by Chiesi) and Aventis (acq. by Sanofi). He received his Bachelor of Science and Doctor of Pharmacy from Rutgers University in NJ.